Carter Ching

This paper develops a virus-like particle-based system for CRISPR gene editing and screening in primary human myeloid cells, identifying TNFAIP3 as a key regulator of inflammatory polarization.

This paper develops a non-viral BCMA CAR-T therapy using CRISPR and 1XX signaling, showing improved safety, potency, and persistence in multiple myeloma.

This study uses base-editing to inactivate a missense mutation in A20ZF7, enhancing CAR-T cell efficacy by reducing exhaustion and improving anti-tumor responses.

The paper develops tools for analyzing T cell behavior from live-cell imaging to improve T cell therapies by studying the effects of genetic modifications on T cell-cancer cell interactions.